DK0918746T3 - Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer - Google Patents
Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauerInfo
- Publication number
- DK0918746T3 DK0918746T3 DK97936479T DK97936479T DK0918746T3 DK 0918746 T3 DK0918746 T3 DK 0918746T3 DK 97936479 T DK97936479 T DK 97936479T DK 97936479 T DK97936479 T DK 97936479T DK 0918746 T3 DK0918746 T3 DK 0918746T3
- Authority
- DK
- Denmark
- Prior art keywords
- carbon atoms
- alkyl
- substituted
- amino
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/243—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/69—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/175—Saturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
- C07C62/10—Saturated compounds containing ether groups, groups, groups, or groups with a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69559996A | 1996-08-12 | 1996-08-12 | |
PCT/US1997/014098 WO1998006692A1 (en) | 1996-08-12 | 1997-08-11 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0918746T3 true DK0918746T3 (da) | 2003-08-04 |
Family
ID=24793682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97936479T DK0918746T3 (da) | 1996-08-12 | 1997-08-11 | Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer |
Country Status (21)
Country | Link |
---|---|
US (6) | US5929117A (da) |
EP (2) | EP0918746B1 (da) |
JP (2) | JP4214537B2 (da) |
KR (2) | KR100539030B1 (da) |
CN (1) | CN1263731C (da) |
AT (2) | ATE418536T1 (da) |
AU (1) | AU729247B2 (da) |
CA (1) | CA2262906C (da) |
CZ (1) | CZ299810B6 (da) |
DE (2) | DE69720735T9 (da) |
DK (1) | DK0918746T3 (da) |
ES (2) | ES2197359T3 (da) |
FI (1) | FI990180A (da) |
HK (1) | HK1021814A1 (da) |
HU (1) | HUP9904569A3 (da) |
NZ (1) | NZ334148A (da) |
PL (1) | PL188835B1 (da) |
PT (1) | PT918746E (da) |
RU (1) | RU2188819C2 (da) |
SK (1) | SK17799A3 (da) |
WO (1) | WO1998006692A1 (da) |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
EP0918746B1 (en) * | 1996-08-12 | 2003-04-09 | Celgene Corporation | Immunotherapeutic agents and their use in the reduction of cytokine levels |
US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
AU784045B2 (en) * | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
GB9930616D0 (en) * | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
CA2395832A1 (en) | 2000-01-25 | 2001-08-02 | Genentech, Inc. | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
NZ521937A (en) * | 2000-03-31 | 2004-08-27 | Celgene Corp | Inhibition of cyclooxygenase-2 activity |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
IT1317049B1 (it) * | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
GB0028702D0 (en) * | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
WO2002064083A2 (en) * | 2000-11-30 | 2002-08-22 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
NZ530765A (en) | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
US6886964B2 (en) * | 2001-06-26 | 2005-05-03 | Allan Gardiner | Illuminator with filter array and bandwidth controller |
AUPS145602A0 (en) * | 2002-03-28 | 2002-05-09 | Commonwealth Scientific And Industrial Research Organisation | Composition and method for killing tumours |
US20050148034A1 (en) * | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
NZ570777A (en) * | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
CN103393695A (zh) | 2002-05-17 | 2013-11-20 | 细胞基因公司 | 用于治疗和控制多发性骨髓瘤的方法及组合物 |
EP1382969A1 (en) * | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
JP2006510606A (ja) * | 2002-10-15 | 2006-03-30 | セルジーン・コーポレーション | 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物 |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
JP2006508950A (ja) * | 2002-10-31 | 2006-03-16 | セルジーン・コーポレーション | 黄斑変性の治療用組成物 |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
MXPA05004780A (es) | 2002-11-06 | 2005-10-05 | Celgene Corp | Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos. |
CA2505003A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
NZ540547A (en) * | 2002-11-18 | 2008-03-28 | Celgene Corp | Use of compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide for inhibiting TNF-alpha production |
JP2006517191A (ja) * | 2002-12-30 | 2006-07-20 | アムジエン・インコーポレーテツド | 共刺激因子を用いた併用療法 |
DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
US7470723B2 (en) | 2003-03-05 | 2008-12-30 | Celgene Corporation | Diphenylethylene compounds and uses thereof |
JP2006519874A (ja) * | 2003-03-05 | 2006-08-31 | セルジーン・コーポレーション | ジフェニルエチレン化合物およびその使用 |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
US20050256132A1 (en) * | 2003-04-30 | 2005-11-17 | Wyeth | Use of ER selective NF-kB inhibitors for the treatment of sepsis |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
ZA200603718B (en) * | 2003-11-06 | 2007-09-26 | Celgene Corp | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
EP2065383A1 (en) | 2003-11-19 | 2009-06-03 | Signal Pharmaceuticals, Inc. | Indazole compounds and methods of use thereof as protein kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
EP1737453A4 (en) | 2004-03-22 | 2008-11-26 | Celgene Corp | METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
BRPI0418742A (pt) * | 2004-04-14 | 2007-09-11 | Celgene Corp | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit |
WO2005110085A2 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
AU2005237490A1 (en) * | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
WO2005102317A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
US7425580B2 (en) * | 2004-05-19 | 2008-09-16 | Wyeth | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands |
US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
BRPI0514857A (pt) | 2004-09-03 | 2008-05-06 | Celgene Corp | composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central |
CA2579291C (en) * | 2004-09-03 | 2011-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
WO2006050057A2 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
CN101102771A (zh) * | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
KR20080026198A (ko) * | 2005-06-30 | 2008-03-24 | 안트로제네시스 코포레이션 | 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원 |
WO2007005972A1 (en) * | 2005-06-30 | 2007-01-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
EP1919365A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
US7928280B2 (en) * | 2005-07-13 | 2011-04-19 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
DE602006020300D1 (de) | 2005-09-01 | 2011-04-07 | Celgene Corp | Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten |
US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
NZ597304A (en) * | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
CN101374941A (zh) * | 2005-12-29 | 2009-02-25 | 人类起源公司 | 采集和保存胎盘干细胞的改良组合物及其使用方法 |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
BRPI0710636A2 (pt) * | 2006-04-21 | 2011-08-23 | Centocor Inc | antagonistas de cxcl 31 e o uso dos mesmos para o tratamento de doenças inflamatórias |
US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
TWI436761B (zh) * | 2006-06-19 | 2014-05-11 | Otsuka Pharma Co Ltd | 使用噻唑衍生物之方法 |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
JP5769925B2 (ja) | 2006-10-06 | 2015-08-26 | アントフロゲネシス コーポレーション | ヒト胎盤コラーゲン組成物、並びにそれらの製造方法及び使用方法 |
US7750048B2 (en) * | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
CN101688177A (zh) | 2007-02-12 | 2010-03-31 | 人类起源公司 | 来自贴壁胎盘干细胞的肝细胞和软骨细胞;以及cd34+、cd45-胎盘干细胞富集的细胞群 |
CN101657206B (zh) | 2007-02-12 | 2013-07-03 | 人类起源公司 | 利用胎盘干细胞治疗炎性疾病 |
EP2076124A4 (en) | 2007-04-20 | 2011-08-03 | Acucela Inc | STYRENYL DERIVATIVE COMPOUNDS FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND SUFFERING |
US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
CN101878034B (zh) | 2007-09-28 | 2013-11-20 | 细胞基因细胞疗法公司 | 使用人胎盘灌洗液和人来自胎盘的中间体自然杀伤细胞的肿瘤抑制 |
US8076516B2 (en) | 2007-11-01 | 2011-12-13 | Acucela, Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
US7964354B2 (en) * | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
US20090232796A1 (en) * | 2008-02-20 | 2009-09-17 | Corral Laura G | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
PL2259675T3 (pl) * | 2008-02-22 | 2016-03-31 | Basf Se | Kompozycje grzybobójcze zawierające 3’-bromo-2,3,4,6’-tetrametoksy-2’-6-dimetylobenzofenon |
FR2932180B1 (fr) * | 2008-06-04 | 2012-08-10 | Centre Nat Rech Scient | Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline |
PE20151143A1 (es) | 2009-02-10 | 2015-08-07 | Celgene Corp | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis |
NZ595440A (en) | 2009-03-25 | 2014-05-30 | Anthrogenesis Corp | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
EP2851070A1 (en) | 2010-01-05 | 2015-03-25 | Celgene Corporation | A combination of lenalidomide and artesunate/artemisone for treating cancer |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
BR112012032217A2 (pt) | 2010-06-15 | 2016-10-25 | Celgene Corp | métodos de predição de se um paciente será responsivo a um tratamento para psoríase, para monitorar a resposta de paciente a um tratamento para psoríase e para monitorar a aceitação do paciente por um protocolo de tratamento com droga para psoríase |
US20140031325A1 (en) | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
MX2013012083A (es) | 2011-04-18 | 2014-04-16 | Celgene Corp | Biomarcadores para el tratamiento de mieloma multiple. |
JP6016892B2 (ja) | 2011-04-29 | 2016-10-26 | セルジーン コーポレイション | セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法 |
CN113559126A (zh) | 2011-06-01 | 2021-10-29 | 人类起源公司 | 利用胎盘干细胞治疗疼痛 |
CN102697757B (zh) * | 2012-05-18 | 2014-06-04 | 广州军区广州总医院 | 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用 |
CN102675074A (zh) * | 2012-05-25 | 2012-09-19 | 江西华士药业有限公司 | 环丙唑醇关键中间体1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法 |
US10335482B2 (en) | 2012-06-06 | 2019-07-02 | Bionor Immuno As | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer |
WO2014004990A2 (en) | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
EP3622960A1 (en) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natural killer cells from placenta |
JP6493692B2 (ja) | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたtリンパ球 |
WO2014172429A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
GB201321739D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015175956A1 (en) | 2014-05-16 | 2015-11-19 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
EP3313818B1 (en) | 2015-06-26 | 2023-11-08 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
US20200246393A1 (en) | 2017-09-28 | 2020-08-06 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
CN108047008A (zh) * | 2017-12-18 | 2018-05-18 | 蚌埠学院 | 一种3,4-二甲氧基二苯甲酮的制备方法 |
US11401336B2 (en) | 2018-02-21 | 2022-08-02 | Celgene Corporation | BCMA-binding antibodies and uses thereof |
CA3196218A1 (en) | 2020-10-25 | 2022-04-28 | Philipp SPYCHER | Means and methods for producing antibody-linker conjugates |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4043887A (en) * | 1977-01-17 | 1977-08-23 | Eastman Kodak Company | Benzophenone initiators for the photopolymerization of unsaturated compounds |
US4420479A (en) | 1982-04-08 | 1983-12-13 | Eli Lilly And Company | Olefinic benzimidazoles, formulations, and antiviral methods |
US4492708A (en) | 1982-09-27 | 1985-01-08 | Eli Lilly And Company | Antiviral benzimidazoles |
US5135940A (en) * | 1982-09-23 | 1992-08-04 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
JPS58188868A (ja) | 1983-04-08 | 1983-11-04 | イ−ライ・リリ−・アンド・カンパニ− | オレフイン系ベンズイミダゾ−ル類 |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
DE3525623A1 (de) * | 1985-07-18 | 1987-01-22 | Celamerck Gmbh & Co Kg | Fungizid wirksame acrylsaeureamide |
CA1317594C (en) | 1987-10-21 | 1993-05-11 | Chung-Ho Park | Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
GB8901864D0 (en) * | 1989-01-27 | 1989-03-15 | Imi Cornelius Uk Ltd | Beverage dispensing apparatus |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PT93909B (pt) * | 1989-04-28 | 1996-10-31 | Sankyo Co | Processo para a preparacao de novos derivados n-acriloil-piperazina com actividade antagonista de paf |
US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP2863264B2 (ja) * | 1990-05-21 | 1999-03-03 | 日本蒸溜工業株式会社 | 含フッ素n,n,n’,n’―テトラアリールベンジジン誘導体およびその製造方法 |
JPH0566591A (ja) | 1991-09-10 | 1993-03-19 | Canon Inc | 電子写真感光体、該電子写真感光体を備えた電子写真装置並びにフアクシミリ |
US5223714A (en) | 1991-11-26 | 1993-06-29 | Ashland Oil, Inc. | Process for predicting properties of multi-component fluid blends |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
DE4220983A1 (de) * | 1992-06-26 | 1994-01-05 | Bayer Ag | Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate |
DE59307823D1 (de) | 1992-08-17 | 1998-01-22 | Emitec Emissionstechnologie | Verfahren zur überwachung der funktion eines katalytischen konverters |
GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
TW263495B (da) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
GB9326600D0 (en) * | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
US5591776A (en) * | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
IT1274549B (it) * | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
EP0918746B1 (en) * | 1996-08-12 | 2003-04-09 | Celgene Corporation | Immunotherapeutic agents and their use in the reduction of cytokine levels |
CN1265590A (zh) * | 1997-07-31 | 2000-09-06 | 赛尔金有限公司 | 取代的链烷异羟肟酸及降低肿瘤坏死因子α水平的方法 |
US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
AU4849199A (en) | 1998-07-01 | 2000-01-24 | Celgro | Fungal growth inhibitors |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) * | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
CA2511843C (en) * | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
JP2006519874A (ja) * | 2003-03-05 | 2006-08-31 | セルジーン・コーポレーション | ジフェニルエチレン化合物およびその使用 |
CA2518513C (en) * | 2003-03-12 | 2014-05-20 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
AU2004220457A1 (en) * | 2003-03-12 | 2004-09-23 | Celgene Corporation | 7-amino- isoindolyl compounds amd their pharmaceutical uses |
-
1997
- 1997-08-11 EP EP97936479A patent/EP0918746B1/en not_active Expired - Lifetime
- 1997-08-11 PL PL97331605A patent/PL188835B1/pl not_active IP Right Cessation
- 1997-08-11 ES ES97936479T patent/ES2197359T3/es not_active Expired - Lifetime
- 1997-08-11 ES ES03002806T patent/ES2315435T3/es not_active Expired - Lifetime
- 1997-08-11 AT AT03002806T patent/ATE418536T1/de not_active IP Right Cessation
- 1997-08-11 CA CA002262906A patent/CA2262906C/en not_active Expired - Fee Related
- 1997-08-11 DK DK97936479T patent/DK0918746T3/da active
- 1997-08-11 KR KR10-1999-7001102A patent/KR100539030B1/ko not_active IP Right Cessation
- 1997-08-11 CN CNB971972516A patent/CN1263731C/zh not_active Expired - Fee Related
- 1997-08-11 EP EP03002806A patent/EP1361210B1/en not_active Expired - Lifetime
- 1997-08-11 CZ CZ0043999A patent/CZ299810B6/cs not_active IP Right Cessation
- 1997-08-11 NZ NZ334148A patent/NZ334148A/en unknown
- 1997-08-11 US US08/909,201 patent/US5929117A/en not_active Expired - Fee Related
- 1997-08-11 JP JP50994498A patent/JP4214537B2/ja not_active Expired - Fee Related
- 1997-08-11 RU RU99104523/04A patent/RU2188819C2/ru not_active IP Right Cessation
- 1997-08-11 AT AT97936479T patent/ATE236872T1/de not_active IP Right Cessation
- 1997-08-11 DE DE69720735T patent/DE69720735T9/de not_active Expired - Fee Related
- 1997-08-11 DE DE69739181T patent/DE69739181D1/de not_active Expired - Fee Related
- 1997-08-11 SK SK177-99A patent/SK17799A3/sk unknown
- 1997-08-11 HU HU9904569A patent/HUP9904569A3/hu unknown
- 1997-08-11 KR KR10-2005-7009821A patent/KR100539031B1/ko not_active IP Right Cessation
- 1997-08-11 WO PCT/US1997/014098 patent/WO1998006692A1/en active Application Filing
- 1997-08-11 AU AU39138/97A patent/AU729247B2/en not_active Ceased
- 1997-08-11 PT PT97936479T patent/PT918746E/pt unknown
-
1999
- 1999-02-01 FI FI990180A patent/FI990180A/fi unknown
- 1999-03-18 US US09/271,683 patent/US6130226A/en not_active Expired - Fee Related
- 1999-12-02 HK HK99105649A patent/HK1021814A1/xx not_active IP Right Cessation
-
2000
- 2000-08-16 US US09/639,757 patent/US6262101B1/en not_active Expired - Fee Related
-
2001
- 2001-07-16 US US09/906,155 patent/US6479554B2/en not_active Expired - Fee Related
-
2002
- 2002-09-13 US US10/243,927 patent/US20030045726A1/en not_active Abandoned
-
2003
- 2003-07-17 US US10/622,618 patent/US7019030B2/en not_active Expired - Fee Related
-
2008
- 2008-01-25 JP JP2008015067A patent/JP2008143912A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0918746T3 (da) | Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer | |
CA2233975A1 (en) | Succinimide and maleimide cytokine inhibitors | |
DE69535195D1 (de) | Substituierte imide als tnf inhibitoren | |
EA199800882A1 (ru) | Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно) | |
DK0851857T3 (da) | Inhibitorer af tumornekrosefaktor-alpha | |
RU99113849A (ru) | Иммунотерапевтические имиды/амиды в качестве ингибитора фдэ iv и фно | |
WO1998024763A3 (en) | Immunotherapeutic imides/amides as pde iv and tnf inhibitors | |
NO921719L (no) | Fosfono/biaryl-substituerte dipeptidderivater | |
EA199900953A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p38 КИНАЗЫ | |
KR930021654A (ko) | 전립선 이상비대 치료용 스테로이드 유도체, 그의 제조방법 및 용도 | |
IE46288L (en) | 4,5,6,7-TETRAHYDRO-THIENO [2,3-c] AND [3,2-c] PYRIDINES | |
FR2677023B1 (fr) | Derives de coumarine hydrosolubles, leur preparation et leur utilisation comme substrat d'enzyme. | |
MY104955A (en) | Pyrroloquinoline and pyrrolophemothiazine carboxamides and related compounds. | |
IE810728L (en) | Pyrazole derivatives. | |
JPS54132544A (en) | Novel anthranilic acid derivative | |
ES455023A1 (es) | Procedimiento para preparar derivados de tieno-(3, 2-c)-pi- ridina. | |
WO2001085875A3 (en) | Diesel fuel stabiliser | |
JPS6450807A (en) | Photo-polymerizable dental material | |
GB1196784A (en) | Quinoxaline Derivatives | |
ES461254A1 (es) | Un procedimiento para la preparacion de derivados de 1,4-di-hidropiridina. | |
ES484853A1 (es) | Procedimiento para preparar derivados de 1-hidroximetil-1- oxo-prostano de las series e, a y f. | |
JPS55164683A (en) | Spirolactone compound and its preparation | |
JPS52130821A (en) | Tetrachloronaphthoylene-aryleneimidazole derivative and its production |